Monterey Bio Acquisition (MTRY) Stock Analysis

What Monterey Bio Acquisition does

Monterey Bio Acquisition Corporation currently lacks substantial operational activities. Its primary goal is to achieve a business combination—including but not limited to mergers, capital stock exchanges, asset acquisitions, or reorganizations—with companies in the biotechnology industry. The firm, established in 2020, was formerly known as Chardan FinTech Acquisition Corp. and rebranded to Monterey Bio Acquisition Corporation in April 2021. It is headquartered in New York, New York.

Key metrics

ETFs linked to MTRY

Broad-market and Financial Services sector ETFs an investor holding Monterey Bio Acquisition is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how MTRY fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Frequently asked questions

What is the ticker symbol for Monterey Bio Acquisition?

Monterey Bio Acquisition trades under the ticker MTRY on NASDAQ.

Which exchange is MTRY listed on?

MTRY is listed on NASDAQ.

What sector does Monterey Bio Acquisition operate in?

Monterey Bio Acquisition is classified in the Financial Services sector (Shell Companies industry).

How can PortView help analyze MTRY in a portfolio?

PortView shows MTRY's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.